MET and breast cancer: We later reported that, in various human and mouse cells, including lung and breast cancer cells, β1 siRNA KD, KO or the expression of a β1 form mutated in its two NXXY domains, prevented the sustained phosphorylation of ERK1/2 stimulated by c-Met, when activated by HGF or constitutively by an oncogenic alteration.